The product is produced after purification and aluminium adjuvant adsorption of the VLP that is formed   by purification and recombination of the main capsid protein L1 of human papillomavirus (HPV) type-6, type-11, type-16, type-18, type-31, type-33, type-35, type-39, type-45, type-51, type-52, type-56, type-58, type-59 and type-68 expressed by Hansenula polymorpha, with no preservative contained.

It can prevent cervical cancer, vulvar cancer, vaginal cancer, oropharyngeal cancer, head-neck cancer, genital warts, genital precancerous lesions, including cervical intraepithelial neoplasis CIN 1 to CIN 3, adenocarcinoma in situ of cervix, vulva intraepithelial neoplasia stage I to III, vagina intraepithelial neoplasia stage I to III, anal cancer, penile cancer, perineal cancer, perianal cancer, anal-external genitals precancerous lesions, including penis/perianal/perineal intraepithelial neoplasia stage I to III, and anal intraepithelial neoplasia stage I to III, etc., that are caused by the above-mentioned human papillomaviruses.